DNER — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL881208	1.00	2/20
SCHEMBL881227	1.00	2/20
SCHEMBL881473	1.00	2/20
SCHEMBL873173	0.84	2/20
SCHEMBL881274	0.84	2/20
SCHEMBL7480681	0.84	2/20
SCHEMBL881202	0.83	2/20
SCHEMBL881214	0.81	2/20
SCHEMBL881223	0.80	2/20
SCHEMBL881276	0.77	2/20
SCHEMBL881281	0.76	2/20
SCHEMBL3209712	0.72	2/20
SCHEMBL881277	0.70	2/20
SCHEMBL9038760	0.70	2/20
SCHEMBL3202033	0.69	2/20
SCHEMBL881272	0.69	2/20
SCHEMBL3200668	0.69	2/20
SCHEMBL3198936	0.68	2/20
SCHEMBL2544021	0.68	2/20
SCHEMBL3197736	0.67	2/20

Clinical trials — most relevant to DNER by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis	PHASE2	COMPLETED
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer	PHASE2	COMPLETED
caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.	PHASE2	UNKNOWN
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer	PHASE1/PHASE2	COMPLETED
NG2 and DLL3 CAR-T Cells Targeting Melanoma	PHASE1/PHASE2	RECRUITING
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	PHASE2	COMPLETED
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance	PHASE2	COMPLETED
EGF Ointment for Erlotinib Skin Lesion	PHASE2	COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors	PHASE1	COMPLETED
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC	PHASE1	RECRUITING
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery	PHASE1	COMPLETED
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors	PHASE1	COMPLETED
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients	PHASE1	COMPLETED
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)	PHASE1	COMPLETED
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	PHASE1	COMPLETED
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia	PHASE1	WITHDRAWN
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing	PHASE1	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741	nan	COMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment	nan	ENROLLING_BY_INVITATION
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma	nan	UNKNOWN
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients	nan	UNKNOWN
Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DNER binder may also engage these)

Protein	Name	Similarity
Q8JZM4	—	1.000	Q8JZM4 →
Q61483	—	0.993	Q61483 →
Q9NR61	—	0.993	Q9NR61 →
O00548	—	0.992	O00548 →
Q9ET61	—	0.991	Q9ET61 →
D3ZHH1	—	0.990	D3ZHH1 →
Q8R0S6	—	0.989	Q8R0S6 →
Q9NQ36	—	0.989	Q9NQ36 →
P18168	—	0.988	P18168 →
P78504	—	0.988	P78504 →
O61307	—	0.988	O61307 →
P15306	—	0.987	P15306 →
P0DPK3	—	0.987	P0DPK3 →
Q8TEU8	—	0.987	Q8TEU8 →
Q9R097	—	0.987	Q9R097 →
O57409	—	0.987	O57409 →
A0A096LNW5	—	0.987	A0A096LNW5 →
Q63722	—	0.987	Q63722 →
Q8UWJ4	—	0.987	Q8UWJ4 →
Q9Z1P5	—	0.987	Q9Z1P5 →
Q7TQN3	—	0.987	Q7TQN3 →
Q9JI71	—	0.987	Q9JI71 →
Q9JJS0	—	0.987	Q9JJS0 →
Q8IWY4	—	0.987	Q8IWY4 →
Q08E66	—	0.987	Q08E66 →
B8JI71	—	0.986	B8JI71 →
Q8BH27	—	0.986	Q8BH27 →
Q9NPY3	—	0.986	Q9NPY3 →
O89103	—	0.986	O89103 →
Q6NZL8	—	0.986	Q6NZL8 →